Aclarion, Inc. Warrant - ACONW STOCK NEWS

Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.

Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.

With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.

Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.

Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.

Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.

Aclarion's Nociscan Solution will be utilized in the LIFEHAB Trial in Norway, a randomized controlled trial comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial aims to enroll 202 patients with back pain greater than 1 year in duration. Nociscan is the first evidence-supported SaaS platform to help physicians distinguish between painful and nonpainful discs in the lumbar spine using chemical biomarkers and proprietary algorithms. Aclarion sees this trial as a significant step towards successful reimbursement in Norway's national health insurance system, targeting enrollment to start in the second quarter of 2024.

Aclarion, Inc. confirms the predictive value of Nociscan for identifying painful discs. Nociscan demonstrated 100% sensitivity and 80% specificity compared to provocative discography, providing surgeons with better information. The clinical paper published in the International Journal of Spine Surgery establishes Nociscan as a noninvasive method to identify painful lumbar discs, potentially improving surgical outcomes.

Aclarion, Inc. closes public offering of 5,175,000 units, raising approximately $3.0 million. Each unit sold at $0.58 includes one share of common stock (or pre-funded warrant), and two common warrants. The common warrants are exercisable at $0.58 per share and expire in five years. Maxim Group LLC acted as the sole placement agent. The offering was made under a registration statement declared effective by the SEC.

Aclarion, Inc. announced the pricing of a public offering of 5,175,000 units at $0.58 per unit, expecting gross proceeds of approximately $3.0 million. The offering includes common stock, pre-funded warrants, and common warrants, with Maxim Group LLC acting as the sole placement agent. The offering is expected to close on February 27, 2024.

Aclarion, Inc. (ACON) has initiated the CLARITY trial to validate superior surgical outcomes using Nociscan technology. The recent financing transactions have significantly reduced debt and increased available cash, enabling the company to achieve key milestones. The strategic partnership with Alphatec is expected to onboard 5 additional Key Opinion Leader surgeons and increase Nociscan orders. The CLARITY trial will enroll up to 300 patients across 8 sites, with principal investigator Nicholas Theodore, MD, leading the study. Aclarion also aims to add 5 new KOL surgeons to the Nociscan network in the first half of 2024 through the strategic partnership with Alphatec.